Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
$1.74
+2.4%
$1.89
$1.58
$16.18
$270K-0.8329,013 shs13,358 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.20
$17.03M1.19170,372 shs4.12 million shs
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
$0.02
$80K1.5923.72 million shs75 shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.87
-0.2%
$4.80
$0.53
$5.25
$49.03M-1.689,566 shs11,370 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
-3.95%-9.57%-12.37%+169,999,900.00%+169,999,900.00%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%-27.13%-70.18%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%-90.00%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%0.00%+3.83%+51.55%+94.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
$44.88M0.01N/AN/A($19.40) per share-0.09
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M18.34N/AN/A($11.55) per share-0.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
-$2.56MN/A0.00N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
0.28
1.14
0.47
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45

Institutional Ownership

CompanyInstitutional Ownership
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
2.55%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Invitae Co. stock logo
NVTA
Invitae
61.28%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%

Insider Ownership

CompanyInsider Ownership
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
42.80%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Invitae Co. stock logo
NVTA
Invitae
0.74%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
38160,00090,000N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionOptionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable

Recent News About These Companies

OpGen Forms Joint Venture with European Bank
OpGen Appoints New COO and Company Secretary
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock Split
OpGen Announced 1-for-10 Reverse Stock Split

New MarketBeat Followers Over Time

Media Sentiment Over Time

Capstone Therapeutics stock logo

Capstone Therapeutics NASDAQ:CAPS

$1.74 +0.04 (+2.35%)
As of 03:59 PM Eastern

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.87 -0.01 (-0.20%)
As of 02:50 PM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.